Otonomy Obtains Rights to Gacyclidine Data From Ipsen to

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Otonomy Obtains Rights to Gacyclidine Data From Ipsen to Support Development of OTO-311 as a Treatment for Tinnitus

SAN DIEGO and PARIS, Nov. 6, 2014 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC ), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the inner and middle ear, and Ipsen (Euronext:IPN) (ADR:IPSEY), a global specialty-driven pharmaceutical company, today announced that they have entered into an exclusive licensing agreement enabling Otonomy to utilize Ipsen's gacyclidine data in the development and registration of OTO-311. OTO-311 is Otonomy's sustained-exposure formulation of gacyclidine, an N-Methyl-D-Aspartate (NMDA) receptor antagonist, in development for the treatment of tinnitus.

"We are pleased to complete this agreement with Ipsen which supports our plan to initiate OTO-311 clinical trials next year," said David A. Weber, Ph.D., President and CEO of Otonomy. "Additionally, we believe that the clinical data set generated by Ipsen provides important insights into gacyclidine's systemic profile that will inform our development of locally administered OTO-311 for the treatment of tinnitus."

"Tinnitus is a debilitating disorder for which there are no FDA-approved drug treatments," said Claude Bertrand, Executive Vice President, Chief Scientific Officer of Ipsen. "Through this agreement, we are pleased that prior R&D studies with gacyclidine, conducted by Ipsen, could support Otonomy's development of OTO-311 for use in a population where there is a need for new therapeutic options."

About the Agreement

Under the terms of the agreement, Otonomy will have an exclusive license to use Ipsen's clinical and non-clinical gacyclidine data to support worldwide development and regulatory filings for OTO-311. These data include non-clinical studies which supported Ipsen's initiation of clinical studies for systemic administration of gacyclidine, and clinical data from several Phase 1 and Phase 2 clinical trials conducted by Ipsen. In total, more than 300 patients were treated with systemic gacyclidine as a potential neuroprotectant in various neurologic trauma indications. Financial terms of the agreement were not disclosed.

About Gacyclidine

Gacyclidine is a potent and selective antagonist of the NMDA receptor. Clinical studies, including pilot studies conducted with gacyclidine, support the use of NMDA receptor antagonists as a potential treatment for tinnitus. OTO-311 utilizes Otonomy's proprietary drug delivery technology to achieve sustained exposure of gacyclidine in the inner ear from a single intratympanic (IT) injection.

About Tinnitus

Tinnitus is the medical term for hearing noise when there is no outside source of the sound. It is often described as a ringing in the ear but can also sound like roaring, clicking, hissing or buzzing. The American Tinnitus Association 1 reports that approximately 16 million patients in the United States have tinnitus symptoms severe enough to seek medical attention, and about two million patients cannot function on a normal day-to-day basis. Furthermore, the United States Department of Defense reports that tinnitus accounts for the most prevalent service-connected disability among veterans and that the costs of service-related tinnitus are estimated to exceed $2 billion 2 . While the most common cause of tinnitus is exposure to loud noise, a number of other factors can be involved including heart or blood vessel problems, hormonal changes in women, ear and sinus infections, certain medications and thyroid problems. People with severe tinnitus may have trouble hearing, working, and sleeping. At this time, there is no cure for tinnitus and there are no FDA-approved drugs for treating this debilitating condition.

About Otonomy

Otonomy is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the ear. Otonomy's proprietary technology provides sustained exposure of drugs to the middle and inner ear following a single intratympanic injection. Otonomy has three product candidates in development. AuriPro™ is an antibiotic that has completed Phase 3 clinical trials in pediatric patients with middle ear effusion at the time of tympanostomy tube placement surgery. OTO-104 is a steroid that is in the first of two pivotal clinical studies for the treatment of patients with Ménière's disease. OTO-311 is an NMDA receptor antagonist in development as a treatment for tinnitus. For additional information, please visit www.otonomy.com .

About Ipsen

Ipsen is a global specialty-driven pharmaceutical company with total sales exceeding €1.2 billion in 2013. Ipsen's ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its development strategy is supported by 3 franchises: neurology, endocrinology and uro-oncology. Moreover, the Group has an active policy of partnerships. Ipsen's R&D is focused on its innovative and differentiated technological platforms, peptides and toxins. In 2013, R&D expenditure totaled close to €260 million, representing more than 21% of Group sales. Moreover, Ipsen also has a significant presence in primary care. The Group has close to 4,600 employees worldwide. Ipsen's shares are traded on segment A of Euronext Paris (stock code: IPN, ISIN code: FR0010259150) and eligible to the "Service de Règlement Différé" ("SRD"). The Group is part of the SBF 120 index. Ipsen has implemented a Sponsored Level I American Depositary Receipt (ADR) program, which trade on the over-the-counter market in the United States under the symbol IPSEY. For more information on Ipsen, visit www.ipsen.com .

Otonomy Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, statements concerning Otonomy's plan to initiate OTO-311 clinical trials next year and Otonomy's belief that the clinical data set generated by Ipsen provides important insights into gacyclidine's systemic profile that will inform Otonomy's development of locally administered OTO-311 for the treatment of tinnitus. Forward-looking statements reflect the Company's current views with respect to certain current and future events and are subject to various risks, uncertainties and assumptions that could cause actual results to differ materially. Risks, and uncertainties include, but are not limited to, the risk that clinical drug development involves a lengthy and expensive process with uncertain outcome. The risks, uncertainties and assumptions referred to above are discussed in detail in our reports filed with the Securities and Exchange Commission, including our Prospectus filed on August 13, 2014. The Company does not undertake to publicly update or revise any forward-looking statements to reflect events or circumstances that may arise after the date hereof except as may be required by law.

Ipsen Forward Looking Statements

The forward-looking statements, objectives and targets contained herein are based on the Group's management strategy, current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. All of the above risks could affect the Group's future ability to achieve its financial targets, which were set assuming reasonable macroeconomic conditions based on the information available today. Use of the words "believes," "anticipates" and "expects" and similar expressions are intended to identify forward-looking statements, including the Group's expectations regarding future events, including regulatory filings and determinations. Moreover, the targets described in this document were prepared without taking into account external growth assumptions and potential future acquisitions, which may alter these parameters. These objectives are based on data and assumptions regarded as reasonable by the Group. These targets depend on conditions or facts likely to happen in the future, and not exclusively on historical data. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties, notably the fact that a promising product in early development phase or clinical trial may end up never being launched on the market or reaching its commercial targets, notably for regulatory or competition reasons. The Group must face or might face competition from generic products that might translate into a loss of market share. Furthermore, the Research and Development process involves several stages each of which involves the substantial risk that the Group may fail to achieve its objectives and be forced to abandon its efforts with regards to a product in which it has invested significant sums. Therefore, the Group cannot be certain that favourable results obtained during pre-clinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the product concerned. There can be no guarantees a product will receive the necessary regulatory approvals or that the product will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Other risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the Group's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Group's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. The Group also depends on third parties to develop and market some of its products which could potentially generate substantial royalties; these partners could behave in such ways which could cause damage to the Group's activities and financial results. The Group cannot be certain that its partners will fulfil their obligations. It might be unable to obtain any benefit from those agreements. A default by any of the Group's partners could generate lower revenues than expected. Such situations could have a negative impact on the Group's business, financial position or performance. The Group expressly disclaims any obligation or undertaking to update or revise any forward looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based, unless so required by applicable law. The Group's business is subject to the risk factors outlined in its registration documents filed with the French Autorité des Marchés Financiers.

1 http://www.ata.org/for-patients/faqs

2 http://hearing.health.mil/HearingLoss101/Stat...gures.aspx

Contacts:

OTONOMY  
Media Inquiries  
Canale Communications  
Heidi Chokeir, Ph.D.  
Vice President  
619.849.5377  
heidi@canalecomm.com  
   
Investor Inquiries  
Westwicke Partners  
Robert H. Uhl  
Managing Director  
858.356.5932  
robert.uhl@westwicke.com  
   
IPSEN  
Media  
Didier Véron  
Senior Vice-Président, Public Affairs Brigitte Le Guennec
and Communication Corporate External Communication Manager
Tel.: +33 (0)1 58 33 51 16 Tel.: +33 (0)1 58 33 51 17
Fax: +33 (0)1 58 33 50 58 Fax: +33 (0)1 58 33 50 58
E-mail: didier.veron@ipsen.com E-mail : brigitte.le.guennec@ipsen.com
   
Financial Community  
Stéphane Durant des Aulnois Thomas Peny-Coblentz, CFA
Investor Relations Director Investor Relations Deputy Director
Tel.: +33 (0)1 58 33 60 09 Tel.: +33 (0)1 58 33 56 36
Fax: +33 (0)1 58 33 50 63 Fax: +33 (0)1 58 33 50 63
E-mail: stephane.durant.des.aulnois@ipsen.com E-mail: thomas.peny-coblentz@ipsen.com
Scroll down for more posts ▼

Top 10 Most Recent News Articles

UN Integrity Accelerator Targets Corporate Corruption

Updated Category News Views 114

Corruption rarely arrives wearing a villain costume; it shows up as a rushed payment, a friendly intermediary, or a contract nobody wants examined too closely. That is why the United Nations Global Compact's new Business Integrity Accelerator deserves a sober look. Launched November 18, 2026, the programme is not a magic shield, and nobody should sell it as one. But it...

Continue Reading
Term or Whole Life: Costs, Coverage, and Trade-Offs

Updated Category News Views 10

A life insurance choice can sit quietly in a drawer for years, then become brutally important at exactly the wrong moment. Laura Wood's November 18, 2026 comparison of term and whole life insurance is useful for that reason: it keeps dragging the conversation back to the unglamorous stuff that actually matters—how long coverage lasts, what it costs, and whether a...

Continue Reading
Telit Cinterion Tests Its Defense Connectivity Pitch

Updated Category News Views 76

Defense connectivity is a messy business, and Telit Cinterion is leaning straight into the mess at NATO Edge 2026 in Izmir, Turkey. From November 17 through 19, the company is using Booth L86 to show how several wireless links can live inside one mission-focused setup. That may sound like standard trade-show wallpaper, but the underlying problem is very real: military and...

Continue Reading
LLCP Backs Empower in UK Infrastructure Services Push

Updated Category News Views 31

A majority cheque has landed in a business built around unglamorous work that cannot be wished away: keeping mechanical and electrical systems installed, refurbished and maintained. On November 18, LLCP said it completed a majority investment in London-headquartered Empower Technical Services alongside chief executive Nicholas Manning, co-founders Florian Kronawitter and...

Continue Reading
BKV Energy's $400,000 Loyalty Bet Has a Real Point Behind It

Updated Category News Views 13

Retail power customers rarely send thank-you notes; they switch plans, complain about bills, or quietly vanish. That is why BKV Energy putting more than $400,000 into its third annual ElectroShare payout deserves a harder look than the usual feel-good loyalty announcement. A Retention Expense With Some Teeth The payout has climbed quickly: roughly $113,000 in the first...

Continue Reading
Pacific Surfliner Faces Thanksgiving Capacity Test

Updated Category News Views 49

Thanksgiving traffic on Southern California freeways is its own yearly punishment, and the Pacific Surfliner is making a sensible pitch: leave the car parked and let the coast roll past the window. For travelers, that can be a real relief. For anyone watching public transportation, this is also a useful little stress test of whether a busy state-supported rail corridor...

Continue Reading
Scribd’s First Safety Report Shows Enforcement at Scale

Updated Category News Views 292

Forty-seven million enforcement actions is not a decorative statistic Scribd finally put some hard numbers on a problem most document platforms prefer to discuss in foggy corporate language. Its first transparency report, covering January through June 2026, says the company took more than 47 million moderation actions across Scribd and Slideshare. That is a hulking...

Continue Reading
Wallstreet Sand Hands Its Massive Permian Plant to Wilbanks

Updated Category News Views 139

A sand plant can brag about acreage and horsepower all day, but frac crews remember who kept material arriving when a completion schedule got ugly. That is the real backdrop to PI Holdings and Wallstreet Sand Co. naming Blaine Wilbanks president of both businesses on November 18, 2026. This is not a ceremonial chair swap. Wallstreet has built an enormous Permian sand...

Continue Reading
DocLinq Takes Aim at Care Gaps Between Office Visits

Updated Category News Views 16

Healthcare's most expensive loose ends often pile up after the appointment ends. DocLinq, launched from Columbia, Maryland, is taking a run at that awkward stretch between office visits, where records sit in separate systems, chronic-care follow-up gets uneven, and patients are expected to remember far more than any human reasonably can. This is not a story about AI...

Continue Reading
AI Gives CPA Firms a New Advisory Staffing Math Today

Updated Category News Views 50

Month-end just got a lot less comfortable for firms living on the clock. Netsurit and Southwestern Talent are pitching the Virtual CFO Platform as a way for CPA firms to turn machine-led analysis into advisory work without first building a costly bench of specialists. That is not a cute workflow tweak. It goes straight at the labor model that has kept plenty of accounting...

Continue Reading

Top 5 Most Recently Viewed Articles

EHang's Progress and Financial Results: Navigating Change

Updated Category News Views 389

EHang Reports Its Third Quarter Financial Performance EHang Holdings Limited (NASDAQ: EH), a leader in advanced air mobility, has recently released its unaudited financial results for the third quarter. The company continues to strive towards maintaining its full-year revenue guidance of RMB500 million. In this article, we will highlight key operational and financial...

Continue Reading
Analysts Revise Procter & Gamble Earnings Forecasts Ahead of Q1 Results

Updated Category News Views 107

Procter & Gamble Earnings Forecast The Procter & Gamble Company (NYSE: PG) is on the verge of releasing its first-quarter earnings results. Analysts have been busy revising their forecasts ahead of this pivotal moment for the company. Expectations Leading to Earnings Analysts predict that Procter & Gamble will report quarterly earnings of $1.90 per share, marking an...

Continue Reading
BLM Engages Advocates in Revolutionary Wild Horse Dialogue

Updated Category News Views 244

BLM Partners with Advocates for Wild Horse Management The Bureau of Land Management (BLM) has taken a significant step by inviting a group of citizen advocates to work together on the management of wild horses and burros. This initiative marks an important moment in wild horse conservation, providing a unique opportunity for open conversation between the BLM and...

Continue Reading
Covenant Logistics Announces New Quarterly Cash Dividend Details

Updated Category News Views 137

Covenant Logistics Declares Quarterly Cash Dividend Covenant Logistics Group, Inc. has officially announced a quarterly cash dividend of $0.07 per share, benefiting both Class A and Class B common stockholders. This dividend decision, made by the Company’s board of directors, demonstrates their commitment to returning value to shareholders and reflects the company's...

Continue Reading
Landsbankinn hf. Prepares for Upcoming Q3 2024 Financial Release

Updated Category News Views 57

Landsbankinn hf. Announces Financial Results Release Date Landsbankinn hf. is gearing up to share its financial outcomes for the third quarter of 2024. This important event is scheduled for a Wednesday, and stakeholders are keenly anticipating the insights this release will bring. What to Expect from the Financial Results Investors are always on the lookout for key...

Continue Reading